Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434177 | 0.86 | F10 (0.47) | F10PTGS2KDM1ACYP1A2CYP3A4 | |
| SCHEMBL5432444 | 0.83 | USP2 (0.46) | KDM1A | |
| SCHEMBL5434172 | 0.81 | F10 (0.46) | F10PTGS2KDM1ACYP1A2CYP3A4 | |
| SCHEMBL5435766 | 0.80 | F10 (0.48) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5435560 | 0.74 | F10 (0.43) | F10PTGS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1675835 | 0.72 | F10 (0.50) | F10PTGS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7906874 | 0.71 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL3864241 | 0.71 | F10 (0.60) | F10PTGS2 | |
| SCHEMBL5443405 | 0.70 | F10 (0.51) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5441040 | 0.69 | USP2 (0.45) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | F10 53/4885PTGS2 4045/4885KDM1A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.